Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Relief Therapeutics Hldg Ag (OP:RLFTF)

2.080 +0.065 (+3.23%)
Streaming Delayed Price Updated: 10:51 AM EST, Jan 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Relief Therapeutics Hldg Ag

News headline image
Relief Therapeutics, NRx Pharma Settle Litigation Regarding COVID-19 Treatment Candidate ↗
 
Via Benzinga
News headline image
Daily Biotech Pulse: GSK's Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion's Schizophrenia Candidate ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates ↗
The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment. 
Via Benzinga
News headline image
FDA Rejects Acer Therapeutics - Relief Therapeutics' Urea Cycle Disorder Candidate ↗
 
Via Benzinga
News headline image
The Week Ahead In Biotech (June 5-11): Adcom Test For Novavax, ASCO Presentations, Enzo Biochem Earnings And More ↗
Biotech stocks reversed course along with the broader market and closed the week ending June 3 lower. The sector's lean run thus got extended. 
Via Benzinga
News headline image
Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates ↗
May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month,... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Adagio's Antibody Effective Against Omicron, Sarepta Terminates Gene Therapy Deal, AstraZeneca Inks Oncology Pact ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Says Lead Monoclonal Antibody Effective Against Omicron Variant Adagio... 
Via Benzinga
News headline image
NRx Pharma Files Counterclaim Against Relief Therapeutics Over COVID-19 Candidate Rights ↗
NRx Pharmaceuticals Inc (NASDAQ: NRXP) has filed a counterclaim against its former partner, Relief Therapeutics Holdings (OTC: RLFTF), in an ongoing... 
Via Benzinga
News headline image
NRXP Stock Alert: The Covid-19 News Lifting NRx Pharmaceuticals Today ↗
News of a potential Covid-19 treatment breakthrough has NRXP stock rising today. Here's what you need to know about this FDA filing. 
Via InvestorPlace
News headline image
BYND Stock: 11 Things for Plant-Based Investors to Know About the KFC Beyond Meat ‘Fried Chicken’ News ↗
Beyond Meat (BYND) stock is on the move today as investors react to news of Yum Brand's (YUM) KFC adopting plant-based fried chicken. 
Via InvestorPlace
News headline image
RLFTF Stock Alert: What Is Going on With Relief Therapeutics Today? ↗
RLFTF stock and NRXP stock are both gaining this morning after NRx Pharmaceuticals filed for emergency use for its Covid-19 treatment. 
Via InvestorPlace
News headline image
Epigenetics, Psychedelics and Stem Cell Therapy are Topics of the Life Sciences Virtual Investor Conference Launching This Thursday ↗
Photo by Chris Montgomery on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial... 
Via Benzinga
News headline image
FDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate ↗
Relief Therapeutics Holding SA's (OTC: RLFTF) collaborating partner NRx Pharmaceuticals Inc (NASDAQ: NRXP) has announced that the FDA has denied... 
Via Benzinga
News headline image
NRx Pharma Stock Nosedives As FDA Strikes Off Its COVID-19 Drug Hopeful ↗
The FDA has declined the emergency use authorization (EUA) for NRx Pharmaceuticals' (NASDAQ: NRXP) Zyesami (aviptadil). The Company is developing... 
Via Benzinga
News headline image
Relief Therapeutics' Subsidiary Posts Early Data For Nasal Spray COVID-19 Treatment ↗
Relief Therapeutics Holding SA's (OTC: RLFTF) wholly-owned subsidiary, APR Applied Pharma Research SA, has reported interim results from its clinical trial of... 
Via Benzinga
News headline image
Why NRx Pharmaceuticals Stock Is Tumbling Today ↗
The drugmaker is being sued by Relief Therapeutics. 
Via The Motley Fool
Topics Lawsuit
News headline image
Acer Therapeutics Stock Jumps As UCD Candidate Is Under FDA Review ↗
The FDA has accepted for review Acer Therapeutics Inc (NASDAQ: ACER) and its partner, Relief Therapeutics Holding SA's (OTC: RLFTF) marketing... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (... 
Via Benzinga
News headline image
Relief Therapeutics' Lead Candidate Gets US Orphan Drug Tag In Sarcoidosis ↗
The FDA has granted Orphan Drug Designation to Relief Therapeutics Holding AG's (OTC: RLFTF) for RLF-100 (aviptadil), an inhaled formulation, for... 
Via Benzinga
News headline image
Why NRX Pharmaceuticals (NRXP) Stock Is Moving Friday? ↗
Extending yesterday's gain, NRx Pharmaceuticals Inc (NASDAQ: NRXP) stock is up more than 26% during the premarket trading on Friday. NRx's stock opened Thursday... 
Via Benzinga
News headline image
NRx Files for Zyesami Emergency Use in Critical COVID-19 Patients With Respiratory Failure ↗
NRx Pharmaceuticals (NASDAQ: NRXP) has applied with FDA requesting Emergency Use Authorization (EUA) for Zyesami (Aviptadil-acetate) for critically ill COVID-19... 
Via Benzinga
News headline image
Review Of Present Therapies For Covid-19 ↗
A summary of authorized drugs for Covid-19, those in development, and those that have failed. 
Via Talk Markets
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.